58. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358(12): 1250-1261.
59. Taylor LG, Canfield SE, Du XL. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer. 2009;115(11): 2388-2399.
60. Nanda A, Chen MH, Braccioforte MH, et al. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease–induced congestive heart failure or myocardial infarction. JAMA. 2009;302(8):866-873.
61. Stanford JL, Feng Z, Hamilton AS, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA. 2000; 283(3):354-360.
62. Harden J, Northouse L, Cimprich B, et al. The influence of developmental life stage in quality of life in survivors of prostate cancer and their partners. J Cancer Surviv. 2008;2(2):84-94.
63. Potosky A, Legler J, Albertsen P, et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst. 2000;92 (19):1582-1592.
64. Tsivian M, Polascik TJ. Focal cryotherapy for prostate cancer. Curr Urol Rep. 2010;11(3):
147-151.
65. Lee HM, Hong JH, Choi HY. High-intensity focused ultrasound therapy for clinically localized prostate cancer. Prostate Cancer Prostatic Dis. 2006;9(4):439-443.
66. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349 (3):215-224.
67. Kramer BS, Hagerty KL, Justman S, et al. Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Clin Oncol. 2009;27 (9):1502-1516.
68. Schellhammer PF, Higano C, Berger ER, et al; IMPACT Study Investigators. A randomized, double-blind, placebo-controlled, multi-center, phase III trial of sipuleucel-T in men with metastatic, androgen-independent prostatic adenocarcinoma (AIPC). Presented at: American Urological Association 104th Annual Scientific Meeting; April 28, 2009; Chicago, IL. Abstract 9.
69. Hamilton RJ, Banez LL, Aronson WJ, et al. Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer. 2010; 116(14):3389-3398.
70. Gutt R, Tonlaar N, Kunnavakkam R, et al. Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J Clin Oncol. 2010;28(16):2653-2659.
71. Kasperzyk JL, Fall K, Mucci LA, et al. One-carbon metabolism-related nutrients and prostate cancer survival. Am J Clin Nutr. 2009;90(3): 561-569.
72. Gaziano JM, Glynn RJ, Christen WG, et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians’ Health Study II randomized controlled trial. JAMA. 2009;301(1): 52-62.